Lifetime Patient Management Greater Expectations: Is TAVI Rising to The Challenge?

Prof Giuseppe Tarantini is the Head of the Interventional Cardiology Unit within the Department of Cardiac, Thoracic, and Vascular Sciences at the University of Padua Medical School, Padua, IT. He is a globally recognised researcher specialising in ischemic heart disease, structural heart disease, and cardiomyopathies.

Prof Tarantini serves as the primary operator for a diverse array of interventional procedures, encompassing coronary interventions (including atherectomies), peripheral interventions (such as carotid and renal procedures), and structural heart interventions (involving ASDs, PFOs, TAVI, and AVP).

In addition to his clinical work, Prof Tarantini is a distinguished faculty member at various international conferences, including Transcatheter Cardiovascular Therapeutics (TCT), the Congresso della Societa Italiana di Cardiologia Invasiva (SICI-GISE), Euro PCR, and the European Society of Cardiology (ESC). He boasts a publication record of 245 clinical…

Prof David Hildick-Smith is Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre - the Regional Specialist Unit. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and, with more than 20 years experience of Interventional Cardiology, is considered one of the country's leading experts in management of Cardiovascular complaints.

A pioneer of Interventional Cardiology, David is recognised internationally as a leader in cardiovascular diagnosis and treatment. 

Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).

Stefan Toggweiler, PD Dr med, is the head of interventional valve therapy at Heart Center Lucerne.